Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 5 Issue 7, July 2006

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News and Analysis

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Raymond Niaura
    • Carole Jones
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Innovation

  • Needle-free liquid jet injectors have been used for over five decades for delivery of numerous vaccines and drugs such as insulin, growth hormones and anaesthetics. Mitragotri reviews jet injectors with respect to their clinical and emerging applications, mechanistic understanding and future prospects.

    • Samir Mitragotri
    Innovation
Top of page ⤴

Review Article

  • Recent advances in our understanding of the signalling pathways activated in inflammation have revealed several potential therapeutic targets. O'Neill reviews these pathways and speculates on the likelihood of drugs being developed that will limit inflammation without a deleterious impact on host defence.

    • Luke A. J. O'Neill
    Review Article
  • The recent success of the B-cell-depleting antibody rituximab — originally developed as a lymphoma therapy — in the treatment of rheumatoid arthritis has stimulated considerable interest in the potential of drugs that can modulate B-cell function to treat autoimmune disorders. Browning discusses the role of B cells in a range of such disorders and analyses approaches to therapeutic B-cell manipulation.

    • Jeffrey L. Browning
    Review Article
  • Telomerase is expressed by cancer cells where it contributes to tumour maintenance, but is absent from most normal cells. Strategies for targeting telomerase therefore provide new opportunities for targeted cancer therapy. Shay and Wright review the current status and future opportunities for telomerase therapeutics.

    • Jerry W. Shay
    • Woodring E. Wright
    Review Article
  • Mass spectrometry is emerging as a powerful analytical tool at various key stages in the drug discovery process. Hofstadler and Sannes-Lowery review the application of electrospray ionization mass spectrometry in the characterization of noncovalent complexes in drug discovery efforts against several classes of target.

    • Steven A. Hofstadler
    • Kristin A. Sannes-Lowery
    Review Article
  • The ubiquitin–proteasome pathway contains a large number of components that are possible drug targets for cancer and other diseases. Nalepaet al. review evidence linking components of this pathway to human disease and discuss potential strategies for therapeutic intervention.

    • Grzegorz Nalepa
    • Mark Rolfe
    • J. Wade Harper
    Review Article
Top of page ⤴

Erratum

Top of page ⤴

Search

Quick links